Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acedopc-dha
- Development stage
- Preclinical
- Lead developer
- Hospices Civils de Lyon
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AceDoPC-DHA (1-acetyl,2-docosahexaenoyl-glycerophosphocholine) is a structured glycerophospholipid designed to efficiently deliver docosahexaenoic acid (DHA) to the brain. It serves as a stabilized analog of the physiological 2-DHA-lysophosphatidylcholine (2-DHA-lysoPC). The incorporation of an acetyl group at the sn-1 position prevents the migration of DHA from the sn-2 to the sn-1 position, thereby preserving the molecule's structural integrity and its affinity for brain-targeting transporters such as Mfsd2a. Developed with involvement from Hospices Civils de Lyon, AceDoPC-DHA is intended to overcome the limitations of standard DHA forms (like triglycerides) in crossing the blood-brain barrier. It has demonstrated neuroprotective properties in experimental models of ischemic stroke and is being investigated for its potential in Alzheimer's disease. Clinical research has focused on its bioavailability and metabolic pathways in humans compared to other lipidic forms of DHA.
- Brand names
- AceDoPC
- Other names
- 1-acetyl-2-docosahexaenoyl-glycerophosphocholine1-acetyl,2-docosahexaenoyl-glycerophosphocholineAceDoPC-DHA
02
Targets
MFSD2A (Major facilitator superfamily domain-containing protein 2A)
Beyond the preview
Go deeper on acedopc-dha.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acedopc-dha.